DRDO provides license to Laurus Labs for manufacturing COVID drug 2-DG
Hyderabad: Hyderabad based Laurus Labs Limited has recently announced that the company has received the licence from Defence Research & Development Organisation (DRDO) to manufacture and market of 2- Deoxy-D-Glucose (2DG).
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country.
"Laurus Labs has already applied with CDSCO for emergency use authroisation (EUA) for 2DG," the company said.
Read also: Laurus Labs reports Rs 297 crore net profit in Q4
Laurus Labs is a research-driven pharmaceutical manufacturing and biotech company headquartered in Hyderabad, India.
The company's major focus areas include anti-retroviral, Hepatitis C and Oncology drugs.
Next Story
